secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0001140361-24-029955
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed-AstraZeneca negotiation for brensocatib in COPD/asthma expires without agreement
--------------------------------------------------------------------------------

- AstraZeneca exercised final option for brensocatib in COPD/asthma on March 8, 2024.
- Negotiation period expired June 12, 2024; no agreement reached.
- Insmed retains full worldwide rights to brensocatib outside COPD/asthma.
- AstraZeneca has no further rights to develop or commercialize brensocatib in any indication.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036124029955/0001140361-24-029955-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036124029955/ef20031070_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-029955

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer